MedTrace Logo

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

NCT04309981 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2023-08-28

No results posted yet for this study

Summary

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

Conditions

Interventions

BIOLOGICAL

Adult differentiated autologous T-cells with anti-BCMA specificity

After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.

Sponsors & Collaborators

  • Fondos ARI (Assistencia Recerca Intensiva)

    collaborator UNKNOWN

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Fondo Social La Caixa

    collaborator UNKNOWN

  • Sara V. Latorre

    lead OTHER

Principal Investigators

  • Carlos Fernandez de Larrea, MD,PhD · Hospital Clinic of Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-27
Primary Completion
2025-04-01
Completion
2025-04-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04309981 on ClinicalTrials.gov